GlassScriptPhysician profile
Peter M Nguyen
NPI 1902976483
$11,868.71
in general payments reported to CMS, 2019-2025
26 companies · $701 in 2025
The $701 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $346 · 2021: $279 · 2022: $119 · 2023: $9,277 · 2024: $690 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,411 · Food and Beverage: $1,779 · Travel and Lodging: $349 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,410.50 |
| Food and Beverage | $1,778.51 |
| Travel and Lodging | $348.74 |
| Education | $129.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $9,002.64 | 2023 | Quviviq |
| Novo Nordisk INC | $686.56 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $262.32 | 2020-2024 | Otezla, Repatha |
| Lilly USA, LLC | $235.55 | 2022-2025 | Mounjaro, Zepbound |
| Janssen Scientific Affairs, LLC | $225.63 | 2025 | Tremfya |
| Pfizer INC. | $222.71 | 2019-2020 | |
| Janssen Biotech, INC. | $216.26 | 2025 | Tremfya |
| Amarin Pharma, INC. | $202.07 | 2019-2021 | |
| Abbott Laboratories | $124.96 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $121.75 | 2024 | Sotyktu |
| Baxter Healthcare | $100.18 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Astellas Pharma US INC | $71.18 | 2023-2025 | Veozah, Myrbetriq |
| Stryker Corporation | $70.68 | 2025 | Mako |
| Medtronic USA, INC. | $69.13 | 2019 | |
| Axsome Therapeutics, INC. | $63.18 | 2024 | Auvelity |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $54.74 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ucb, INC. | $33.94 | 2024 | Bimzelx |
| Endogastric Solutions, INC | $25.32 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $19.88 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.23 | 2025 | |
| Medline Industries LP | $16.34 | 2019 | |
| Integra Lifesciences Corporation | $13.67 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.79 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.